NTLA Research and Charts

NTLA - Intellia Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-08-07 (Delayed quote data 2025-05-09)

Last 8.12	Change ⇓ -0.16 (-1.93%)	Volume 5,135,427
	Open 8.42	High 8.71	Low 8.05

8EMA (Daily) 8.06	40EMA (Daily) 8.29	50EMA (Daily) 8.54	STO (Daily) 46.253	MACD Hist (Daily) 0.072
8EMA (Weekly) 8.373	40EMA (Weekly) 13.50	50EMA (Weekly) 15.20	STO (Weekly) 29.708	MACD Hist (Weekly) 0.548


Company Profile
Intellia Therapeutics Inc is a genome editing company. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema, and ex vivo programs which include Acute Myeloid Leukemia.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.